High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Leukemia Research - United Kingdom
doi 10.1016/j.leukres.2010.07.017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Gemtuzumab Ozogamicin in Children With Relapsed or Refractory Acute Myeloid Leukemia: A Report of Berlin-Frankfurt-Münster Study Group

Haematologica
Hematology
2018English

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients With Relapsed/Refractory Acute Myeloid Leukemia

Advances in Hematology
Hematology
2017English

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Cytarabine Dose for Acute Myeloid Leukemia

New England Journal of Medicine
Medicine
2011English

Antibody-Based Therapy of Acute Myeloid Leukemia With Gemtuzumab Ozogamicin

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Hematology International
2019English

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy